Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy

Table 5

Effect on the treatment group on being in the 100% chimerism on day 100 group versus being in the 86%–99% or <86% chimerism on day 100, adjusting for age and disease type.

Variable	OR	95% CI	value
Treatment (versus BuCy)
FluBu4 with kinetics	0.73	0.17–3.11	.672
FluBu4 without Kinetics	0.25	0.06–1.09	.066
Age at transplant	1.01	0.96–1.06	.790
Disease	1.53	0.57–4.13	.403

Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; OR, odds ratio.